The n-Lorem Foundation, personalized medicine, and CSR
Cytiva supports the n-Lorem Foundation as it develops personalized medicine. The support reflects our sustainability and corporate social responsibility goals to advance health care and have a positive impact on society.
Funding life-saving research and personalized medicine provides hope for patients who struggle to find a cure.
Within Cytiva’s Designing in Sustainability plan is a desire to improve lives and support those at the forefront of research, innovation, and patient care. We are especially interested in supporting initiatives that have a unique role in solving health challenges.
A nano-rare disease is a disease that affects 30 or fewer people in the world. When it comes to these diseases, personalized treatments are often the only viable solution. Collaboration to find cures and support patients is crucial.
In 2021 we began supporting the U.S.-based n-Lorem Foundation, which treats patients who have genetic nano-diseases. These patients often struggle to get a correct diagnosis or have no treatment options available to them. We donated USD 410 000 in equipment and supplies to n-Lorem for research aimed at helping these patients.
The n-Lorem Foundation is the first nonprofit with a mission to create experimental antisense oligonucleotide (ASO) medicines. These medicines are provided to patients for free, for life.
Connor’s story
In n-Lorem’s first year (2020), the foundation expected to receive just a handful of applications for treatment. It received around 50 applications – a clear sign of the demand for this vital and specialized work. The foundation proceeded to treat 20 people.
One of those patients is 11-year-old Connor. Since he was just a few months old, Connor suffered from seizures, developmental delay, and a movement disorder. His mother, Kelley, searched for answers and a treatment and even set up her own biotech research company. But time and time again, she found existing medicines ineffective. In 2019, Kelley met n-Lorem’s founder, Dr. Stanley T. Crooke, who was in the process of setting up the foundation. Dr. Crooke encouraged her to apply for Connor to be one of the foundation’s first patients.
A team of specialists is now working to develop a treatment for Connor’s very particular set of needs. They hope the treatment will help him live a fuller life and give hope to him and his family and to other people living with rare conditions.
About Cytiva
At Cytiva, we believe the key to transforming human health is accessing life-changing therapies. That’s why our 10 000+ associates in more than 40 countries are keenly focused on helping researchers, biopharma companies, and drug manufacturers to advance and accelerate therapeutics for people that need them.
Learn more at cytiva.com.